Hence, the overall risk of CVD and impact of reducing salt intake in this group was lower.
As most CVDs directly impact expression and function of circulating proteins and peptides, the likelihood of identifying CVD-associated changes within this system is significant.
First, glycemic control may not markedly impact CVD outcomes as in nondialysis trials (1– 3), just as statins have less of an effect on CVD in dialysis patients (17).
That has changed, spurred in large part by the huge impact CVD has on people.
Some of the most important factors that impact CVD mortality and morbidly, particularly for people of low-SES, include the following.
Cardiovascular diseases (CVD) have major impact on the mortality and health-related quality of life of people in both developed and developing countries.
Use of other drugs that favorably impact CVD risk (aspirin, statins, and angiotensin enzyme inhibitors) was lower in ADVANCE than in ACCORD or VADT.
Use of other drugs that favorably impact CVD risk (aspirin, statins, ACE inhibitors) was lower in ADVANCE than in the ACCORD or Veterans Affairs Diabetes Trial (VADT).
Use of other drugs that favorably impact CVD risk (aspirin, statins, ACE inhibitors) was lower in ADVANCE than in ACCORD or VADT.
The disparate treatments prescribed to individuals in the DHS, including oral T2D medications and insulin, may also impact CVD outcomes; however, inclusion of these covariates in our models did not substantially change our results (Additional files 1 and 2).
